Journey Medical Corp
About Journey Medical Corp
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $61.2M
- Net income
- -$11.4M
- Total assets
- $94.6M
- Market cap
- $164.4M
- Gross margin
- 66.2%
- Operating margin
- -13.2%
- Net margin
- -18.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $61.9M
- Cost of revenue
- $20.9M
- Gross profit
- $40.9M
- Operating expenses
- $49.1M
- Operating income
- -$8.2M
- Income tax
- $60.0K
- Net income
- -$11.4M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $94.6M
- Current assets
- $66.9M
- Total liabilities
- $62.7M
- Current liabilities
- $37.4M
- Shareholders’ equity
- $31.9M
Cash flow
- Operating cash flow
- -$12.4M
- Investing cash flow
- -$3.8M
- Financing cash flow
- $16.2M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $164.4M
- EPS (diluted)
- $-0.47
- Shares outstanding
- 27.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 12, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.4M in FY2025.
- Revenue declined 2% from FY2021 to FY2025.
- Gross margin of 66.2%, net margin -18.5%.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Journey Medical Corp.
Write a review
News about Journey Medical Corp
News & sentiment via Polygon.io
